Video

Dr. Ruff Analyzes Overall Survival in the VELOUR Trial

Author(s):

Paul Ruff, MD, from the Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival following treatment with ziv-aflibercept in patients with metastatic colorectal cancer, as observed in the VELOUR trial.

Paul Ruff, MD, director of Medical Oncology at the University of Witwatersrand, Johannesburg, South Africa, discusses a time-course analysis of overall survival (OS) following treatment with ziv-aflibercept (Zaltrap) in patients with metastatic colorectal cancer (mCRC), as observed in the VELOUR trial.

The phase III VELOUR trial examined FOLFIRI alone or in combination with the VEGF-targeted fusion protein aflibercept, following progression on an oxaliplatin-based regimen. The trial included 1226 patients with mCRC and the results were the basis for the FDA approval of aflibercept in early August 2012 (Read About the Approval).

The median OS for patients receiving the combination was 13.5 months compared to 12.1 for FOLFIRI alone (HR=0.82, P = .0032). This is equivalent to an approximate 18% reduction in the risk of dying, Ruff explains.

Furthermore, Ruff adds, the survival advantage with aflibercept appears to be sustained over the course of the trial. At 18 months, aflibercept increased survival by 2.6 months, and by 24 months, survival was prolonged by 4.4 months.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity